Our development pipeline illustrates the progress we’re making on Moderna’s clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new vaccines and therapeutics that may have the potential to treat rare diseases like Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA), and prevent disease such as Cytomegalovirus (CMV), Zika and cancers. View the progress of our mRNA clinical pipeline below.

Modality
Program Indication
ID #
Preclinical development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
Core modalities
Prophylactic Vaccines

COVID-19 vaccine

mRNA-1273 mRNA-1273.351/-211 mRNA-1283
mRNA-1283
mRNA-1273.351/-211
Progress: 100%
Progress: 100%
Progress: 100%
Progress: 100%
Progress: 60%

Worldwide
BARDA funded

Cytomegalovirus (CMV) vaccine

mRNA-1647
Progress: 100%
Progress: 100%
Progress: 100%

Worldwide

Human metapneumovirus and parainfluenza virus 3 (hMPV/PIV3) vaccine

mRNA-1653
Phase 1
(Healthy volunteers)
Phase 1b
(Seropositives)
Progress: 100%
Progress: 100%

Worldwide

Zika vaccine

mRNA-1893
Progress: 100%
Progress: 100%

Worldwide
BARDA funded

Respiratory syncytial virus (RSV) vaccine

mRNA-1345
Progress: 100%
Progress: 50%

Worldwide

Epstein-Barr virus (EBV) vaccine

mRNA-1189
Progress: 65%

Worldwide

Flu vaccine

mRNA-1010 mRNA-1020 mRNA-1030
Phase 1/2
mRNA-1010
Progress: 100%
Progress: 50%

Worldwide

HIV vaccine

mRNA-1644 mRNA-1574
Progress: 65%

Worldwide

IAVI/BMGF/NIAID and others funded

Nipah vaccine

mRNA-1215
Progress: 65%

Worldwide

NIH funded

Influenza H7N9 vaccine

mRNA-1851
Progress: 100%
Progress: 99%

Worldwide
Advancing subject to funding

Systemic Secreted & Cell Surface Therapeutics

Antibody against Chikungunya virus

mRNA-1944
Progress: 100%
Progress: 100%

Worldwide

DARPA funded

Relaxin

mRNA-0184
Progress: 65%

Worldwide

PD-L1
Autoimmune hepatitis

mRNA-6981
Progress: 65%

Worldwide

IL-2
Autoimmune disorders

mRNA-6231
Progress: 65%

Worldwide

Exploratory modalities
Cancer Vaccines

Personalized cancer vaccine (PCV)

mRNA-4157
Progress: 100%
Progress: 100%
Progress: 50%

50-50 global profit sharing with Merck

KRAS vaccine

mRNA-5671
Progress: 100%
Progress: 50%

50-50 global profit sharing with Merck

Intratumoral Immuno-Oncology

OX40L
Solid tumors/lymphoma
Advanced ovarian carcinoma (Ph 2 cohort)

mRNA-2416
Solid tumors/lymphoma
Ovarian
Progress: 100%
Progress: 100%
Progress: 50%

Worldwide

OX40L/IL-23/IL-36γ (Triplet)
Solid tumors/lymphoma

mRNA-2752
Progress: 100%
Progress: 40%

Worldwide

IL-12
Solid tumors

MEDI1191
Progress: 100%
Progress: 40%

50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales

Localized Regenerative Therapeutics

VEGF-A
Myocardial ischemia

AZD8601
Progress: 100%
Progress: 100%
Progress: 50%

AZ to pay milestones and royalties

Systemic Intracellular Therapeutics

PCCA/PCCB
Propionic acidemia (PA)

mRNA-3927
Progress: 100%
Progress: 50%

Worldwide

MUT
Methylmalonic acidemia (MMA)

mRNA-3705
Progress: 65%

Worldwide

PAH
Phenylketonuria (PKU)

mRNA-3283
Progress: 65%

Worldwide

G6Pase
Glycogen Storage Disease
Type 1a (GSD1a)

mRNA-3745
Progress: 65%

Worldwide

Abbreviations: AZ, AstraZeneca; CMV, cytomegalovirus; CRC, colorectal cancer; G6Pase, glucose 6-phosphatase; hMPV, human metapneumovirus; IL12, interleukin 12; IL23, interleukin 23; IL36γ, interleukin 36 gamma; MUT, methylmalonyl-CoA mutase; NSCLC, non-small cell lung cancer; PAH, phenylalanine hydroxylase; PCCA/PCCB, propionyl-CoA carboxylase subunit A/B; PCV, personalized cancer vaccine; PIV3, human parainfluenza 3; RSV, respiratory syncytial virus; VEGF-A, vascular endothelial growth factor A.